Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis  by Bursac, Sladana et al.
Biochimica et Biophysica Acta 1842 (2014) 817–830
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReviewActivation of the tumor suppressor p53 upon impairment of
ribosome biogenesis☆Sladana Bursac a, Maja Cokaric Brdovcak a, Giulio Donati b, Sinisa Volarevic a,⁎
a Department of Molecular Medicine and Biotechnology, School of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia
b Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Institut d'Investigacio' Biome'dica de Bellvitge (IDIBELL), 08908 Hospitalet de Llobregat, Barcelona, Spain☆ This article is part of a Special Issue entitled: Role of th
⁎ Corresponding author. Tel.: +385 51 651 120.
E-mail address: sinisa.volarevic@medri.uniri.hr (S. Vol
0925-4439/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2013.08.014a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 August 2013
Accepted 27 August 2013
Available online 26 October 2013
Keywords:
Ribosome biogenesis stress
p53
RPL5
RPL11
5S rRNA
RibosomopathiesErrors in ribosome biogenesis can result in quantitative or qualitative defects in protein synthesis and conse-
quently lead to improper execution of the genetic program and the development of speciﬁc diseases. Evidence
has accumulated over the last decade suggesting that perturbation of ribosome biogenesis triggers a p53-
activating checkpoint signaling pathway, often referred to as the ribosome biogenesis stress checkpoint pathway.
Although itwas originally suggested that p53 has a prominent role in preventing diseases bymonitoring theﬁdelity
of ribosome biogenesis, recentwork has demonstrated that p53 activation upon impairment of ribosome biogenesis
also mediates pathological manifestations in humans. Perturbations of ribosome biogenesis can trigger a
p53-dependent checkpoint signaling pathway independent of DNA damage and the tumor suppressor ARF
through inhibitory interactions of speciﬁc ribosomal components with the p53 negative regulator, Mdm2.
Here we review the recent advancesmade toward understanding of this newly-recognized checkpoint signaling
pathway, its role in health and disease, and discuss possible future directions in this exciting research ﬁeld. This
article is part of a Special Issue entitled: Role of the Nucleolus in Human Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The mammalian ribosome is a complex structure composed of four
RNAs (rRNAs) and 80 distinct proteins (RPs) [1,2]. Increased capacity
for mRNA translation byway of ribosome biogenesis dictates the capac-
ity of cells to grow, proliferate and differentiate [3–6]. Most steps in
ribosome biogenesis are temporally and spatially organized within the
nucleolus, where a 47S rRNA precursor is transcribed by RNA polymer-
ase I, processed andmodiﬁed bymore than 150 non-ribosomal proteins
and 100 small non-coding RNAs into the mature 18S rRNA of the 40S
ribosomal subunit and to 5.8S and 28S rRNAs of the 60S ribosomal
subunit [7–9]. Although the genes for 5S rRNA are transcribed in the
nucleus by RNA polymerase III, 5S rRNA is assembled into the 60S ribo-
somal subunit in the nucleolus [8,10]. The RP mRNAs are transcribed in
the nucleus by RNA polymerase II and translated on cytoplasmic ribo-
somes, imported into the nucleus, and assembled with the rRNA while
the rRNA is processed in the nucleolus [11–15]. Speciﬁc RPs join nascent
60S and 40S subunits during their path from the nucleolus to the
cytoplasm [11,14,15]. In addition to their roles in stabilization and pro-
motion of correct folding of rRNAs for ribosome assembly, RPs are
involved in export of ribosomal precursors and regulation of speciﬁce Nucleolus in Human Disease.
arevic).
ights reserved.steps in protein synthesis [11,14,15]. However, the exact requirement
of individual RPs for different stages of ribosome biogenesis and/or dis-
tinct steps ofmRNA translation process inmammals is just beginning to
be understood [11,14,15].
Given the enormous energy investment in ribosome biogenesis, the
proper execution of this component of the genetic program has high
importance. Errors in this process can result in the development of a
number of pathological conditions. We and others have hypothesized
that molecular mechanisms must have evolved to sense the ﬁdelity of
this critical cellular process to prevent the development of disease
[6,16,17]. The ﬁrst indication of this came from a study using an induc-
ible model for deleting the gene encoding the S6 ribosomal protein,
Rps6, in the liver of adult mice, which led to abrogation of nascent 40S
ribosome biogenesis and abolition of cell proliferation in the liver
following partial hepatectomy [17]. These results could not be simply
attributed to the loss of protein synthetic capacity in these cells as
pre-existing ribosomes provided sufﬁcient translational capacity to
increase liver size in response to a fasting/re-feeding regimen, a process
that primarily involves an increase in cell mass but not in cell number.
These observations suggested the existence of a novel cell cycle check-
point triggered by impaired ribosome biogenesis [17], in amanner anal-
ogous to of checkpoints triggered by DNA damage [18]. Studies over the
last decade have convincingly demonstrated that perturbation of ribo-
some biogenesis activates the tumor suppressor p53 via binding of
several ribosomal components to its negative regulator, Mdm2, inde-
pendent of DNA damage [19–22]. The p53 is best known for its role as
Fig. 1. Impairment of ribosome biogenesis at various steps can trigger p53 upregulation.
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p53, which regulates transcription of many coding and noncoding
genes, with ensuing multiple outcomes including cell cycle arrest, se-
nescence, apoptosis, changes in metabolism, and DNA repair [23,24].
Disruption of these functions allows continuous proliferation, genomic
instability and evolution of stress-damaged cells, resulting in their ille-
gitimate survival and malignancy [24,25]. Given that the loss of wild-
type p53 provides many selective advantages to cells, it comes as no
surprise that half of all humanmalignant tumors havemutationswithin
the TP53 gene [26]. In cancers retaining wild-type p53, the functions of
p53 are likely inactivated by defects in upstream or downstream p53
network components [23]. As an abundance of evidence has shown,
inherited and acquired abnormalities in ribosome function can lead to
tumorigenesis [27,28] and thus it can be speculated that induction of a
p53-dependent checkpoint response might prevent expansion of such
potentially hazardous cells [29]. Although there are some indications
in support of this idea, deﬁnitive evidence has not yet been provided
[30]. Recent evidence has shown that p53 activation upon impairment
of ribosome biogenesis can also be responsible for certain pathological
manifestations in mice and humans [31–35].Inhibition of Pol I transcription, rRNA processing, assembly of ribosomal subunits, RP
nuclear import by depletion of importin 7 (IPO7) or nuclear export of 40S and 60S
ribosomal subunits by the depletion of exportin 1 (XPO1) can lead to p53 upregulation
(indicated by red stars). p53 upregulation by impaired association of the 40S and 60S
subunits has not been unambiguously demonstrated (question mark).2. Impairment of ribosome biogenesis at various stages can activate
the p53 tumor suppressor
2.1. Evidence from cell culture studies
Following the study of mice with liver-speciﬁc inducible deletion of
the Rps6 gene that demonstrated the existence of a previously unrecog-
nized checkpoint triggered as a result of deﬁciency in ribosome
biogenesis [17], Pestov and co-workers provided the ﬁrst evidence
that the p53 tumor suppressor is a component of this pathway [20].
They demonstrated that the expression of dominant negative mutants
of Bop1, which inhibit rRNA processing, prevented cell cycle progres-
sion in a p53-dependent manner. A number of subsequent investiga-
tions have demonstrated that other perturbations of ribosome
biogenesis in cell culture can also trigger the p53 response [22]. That
the inhibition of rRNA transcription can lead to functional alterations
of the nucleolus and upregulation of p53 protein has been demonstrat-
ed in many different ways including: genetic inactivation of the RNA
polymerase I (Pol I) transcription factor TIF-1A [36], blockage of Pol I
transcription factor UBF by microinjection of speciﬁc monoclonal
antibodies [37], silencing the POLR1A gene coding for the Pol I catalytic
subunit [38], treatment with the immunosuppressant mycophenolic
acid [39,40], low concentrations (b10 nM) of actinomycin D, which
intercalates into the GC-rich regions of rDNA [37,41] or the small
molecule compound CX-3543 (quarﬂoxin) that impairs binding of
SL1/TIF-1B to the rDNA promoter leads to functional andmorphological
alterations of the nucleolus and stabilization of p53 protein levels [42].
Furthermore, the inhibition of rRNA processing by treatment with a
chemotherapeutic compound 5-ﬂuorouracil [43,44] or decreased ex-
pression of proteins required for maturation of 18S and 28S rRNA such
as hUTP18 [45], PAK1IP1[46], WDR3[47], WDR12 [45], WDR36 [48],
nucleophosmin (NPM, B23) [49], nucleostemin [50] as well as speciﬁc
RPs of either 40S or 60S [51] including RPS6 [51], RPS9 [52], RPL23
[53–55], RPL7a [51], RPS7 [51,53,54], RPL24 [31], RPL26 [53], RPL29
[56], RPL30 [56], RPL37 [57], RPS14 [58,59], RPS19 [58], RPS15, RPS20
and RPL37 [60] can also induce a p53-mediated stress signal. Addition-
ally, it has been recently demonstrated that the inhibition of RP nuclear
import or nuclear export of ribosomal subunits by depletion of importin
7 (IPO7) or exportin 1 (XPO1), respectively, perturbs ribosome biogen-
esis, and consequently triggers the p53 response [61]. Taken together,
inhibition of ribosome biogenesis at various levels consistently leads
to p53 accumulation (Fig. 1). However, it remains to be determined
how various lesions in ribosome biogenesis are sensed by this p53-
dependent checkpoint mechanism.2.2. Evidence from in vivo studies
The ﬁrst in vivo evidence implicating p53 as the critical checkpoint
component triggered by deﬁciency in ribosome biogenesis was obtain-
ed by studies of mouse lines employing T cell-speciﬁc [21] and ubiqui-
tous deletions of one Rps6 allele [34]. Conditional deletion of one Rps6
allele in T cells inhibited their accumulation in the spleen and lymph
nodes, because of decreased survival. Additionally, T cell receptor-
mediated stimulation of Rps6-heterozygous T cells induced a normal
increase in their size, but cell cycle progression was impaired. Genetic
inactivation of p53 in Rps6-haploinsufﬁcient T cells rescued this prolif-
erative defect and restored normal numbers of T lymphocytes in the
peripheral lymphoid organs, suggesting that the defect in ribosome bio-
genesis activated a p53-dependent apoptosis and cell cycle checkpoints
to prevent the survival and proliferation of defective T lymphocytes
[21]. To investigate the response to Rps6-deﬁciency in thewhole organ-
ism, one Rps6 allele was conditionally deleted in growing mouse
oocytes and Rps6-heterozygous embryos generated [34]. Embryonic
development up to embryonic day 5.5 (E5.5) was unaffected. However,
gastrulating Rps6-heterozygous embryos (E5.5–E7.5) displayed a dra-
matic increase in p53 protein levels, inhibition of cell cycle progression
and apoptosis, which resulted in embryonic lethality at this develop-
mental period, at which under normal conditions ribosome biogenesis
and cell proliferation are dramatically upregulated. Inactivation of p53
in Rps6-heterozygous embryos bypassed this gastrulation checkpoint
and allowed development until E12.5, when they died with diminished
fetal liver erythropoiesis and severe placental defects, most likely
because a defective translation of speciﬁc mRNAs or an uncharacterized
p53-independent checkpoint response [34].
In contrast to Rps6-heterozygous mice, Rpl22-heterozygous mice
showed no obvious pathological phenotype. However, Rpl22-null mice
displayed a selective defect in the development of αβ-lineage but not
γδ T cells, which was rescued in a p53-negative genetic background
[62]. More recently, the role of p53 in the phenotype of the Belly Spot
and Tail (Bst) mouse that carries a hypomorphic mutation in one allele
of the Rpl24 gene has been analyzed [31]. Rpl24Bst/+ mice reach adult-
hood and display a number of pathological phenotypes including
reduced body size, a white ventral middle spot, retinal abnormalities,
a kinked tail, and other skeletal abnormalities. It was demonstrated
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expressed in gastrulating Rpl24Bst/+ embryos. However, the majority of
the animals survive, presumably because levels of p53 protein in these
embryos at E6.5 were signiﬁcantly lower than in Rps6-heterozygote
embryos and thus insufﬁcient to trigger apoptosis and inhibit cell
cycle progression [31,34]. Because the Bst mutation is a hypomorphic
heterozygous mutation, another possibility exists that the expression
level of Rpl24 was above the required threshold for triggering the p53
checkpoint. Interestingly, p53 is aberrantly expressed in highly prolifer-
ative cells in the neural tube of Rpl24Bst/+ embryos at midgestation.
Genetic inactivation of p53 in thesemice largely rescued all pathological
phenotypes, suggesting that they are caused by p53. However, in the
absence of p53 a large majority of Rpl24Bst/+ mice die within two days
of birth, suggesting a novel role for this tumor suppressor in organismal
survival [31]. The study of Rpl27a-heterozygous mice further illustrated
the high phenotypic diversity of RP-deﬁcient mice [63]. These mice
display epidermal hyperpigmentation, low body weight and anemia.
Additionally, they exhibit abnormally low proliferation and high apo-
ptosis levels in the cerebellar granule cell layer, which is probably the
cause of ataxia in these mice. Similar to the above-mentioned RP-
deﬁcient mice, most of pathological phenotypes were rescued in a p53
deﬁcient genetic background [63]. These studies strongly suggested
that p53 activation upon impairment of ribosome biogenesis in RP-
deﬁcient mice is responsible for their speciﬁc pathological manifesta-
tions. However, it will be a huge challenge to identify p53-dependent
biological responses that are triggered by various RP-deﬁciencies
in vivo and determine their role in such diverse pathological
phenotypes.3. Molecular mechanisms of p53 activation
3.1. p53 activation by DNA damage or oncogenes
The major cellular stressors that lead to cancer trigger activation of
the DNA damage response (DDR) and the CDKN2A alternative reading
frame (ARF) signaling pathways, which act as anti-cancer barriers by
activating the tumor suppressor p53 [18,23,64]. Growing evidence
over the past decade has demonstrated that perturbation of various
steps of ribosome biogenesis can activate the p53 tumor suppressor
independent of DNA damage and the ARF tumor suppressor via binding
of several RPs to p53 negative regulator, Mdm2. To better understand
this novel signal transduction pathway, we will brieﬂy describe what
is known regarding p53 activation by DNA damage and oncogenic
activation. In unstressed cells, p53 protein levels and its transcriptional
activity are negatively regulated by Mdm2, a RING ﬁnger E3 ubiquitin
ligase [65,66]. Mdm2 becomes an active E3 upon heterodimerization
with its homolog MdmX, which does not have E3 ligase activity itself
[67–71]. This heterodimer promotes nuclear export of p53 and its
proteasomal degradation viamonoubiquitination or polyubiquitination,
respectively, as well as inhibiting Mdm2 auto-ubiqitination and
degradation [72]. Furthermore, both Mdm2 andMdmX directly repress
p53 transcriptional activity [66,68]. The DDR signaling pathway leads
to post-translational modiﬁcations of both p53 and Mdm2–MdmX,
which disrupts their interaction and increases Mdm2–MdmX auto-
degradation, leading to p53 stabilization and transcriptional activation
[23,73–77]. Oncogenes, such as Ras, c-Myc, E2F, E1A, β-catenin, and
v-abl, accelerate cell cycle progression, inducing stalling and collapse
of DNA replication forks, which in turn leads to formation of DNA
double-stranded breaks (DSB) and p53 activation via the DDR signaling
as described above [78]. Additionally, oncogenes increase the binding of
ARF toMdm2's central acidic domain,which inhibits p53 ubiquitination
and promotes MdmX degradation, thereby activating p53 [64,79–89].
Because Mdm2 is a transcriptional target of p53, an autoregulatory
feedback loop is generated, which ensures that p53 is downregulated
once the stressor or its consequences are removed [66].3.2. Regulation of p53 activation upon impairment of ribosome biogenesis:
the central role of RPL5 and RPL11
The ﬁrst suggestion that RPs may play a role in p53 activation came
from the observation that RPL5 forms an extraribosomal complex with
Mdm2, p53 and 5S rRNA [90]. Surprisingly, this ﬁnding did not attract
much attention at that time. However, a decade ago, a few landmark
studies implicated RPL5 and RPL11 as Mdm2 binding partners that
block the E3 function of Mdm2 to promote p53 accumulation [91–93].
The fact that the depletion of either RPL5 or RPL11 is sufﬁcient to
suppress p53 upregulation upon inhibition of ribosome biogenesis at
various levels suggests that RPL5 and RPL11, in a mutually dependent
manner, are essential for this response [19,22,53,54,94,95]. The interac-
tion between RPL5 and RPL11withMdm2 does not seem to be a unique
phenomenon since it was shown that overexpressed RPL23 [55,93,96],
RPL26 [97,98], RPS3 [99], RPS7 [100,101], RPS14 [59], RPS25 [102],
RPS27A [103], RPS27, RPS27L [104], RPS15, RPS20 and RPL37 [60] can
bind to Mdm2 and inhibit the ubiquitin protein ligase function toward
p53, leading to p53 upregulation.
Given that RPs are among the most abundant proteins in mammali-
an cells and are highly basic, and thus can speciﬁcally or non-speciﬁcally
interact with other proteins, experiments in which overexpressed RPs
were used to demonstrate their interaction with the acidic domain of
Mdm2 must be interpreted with caution [105]. Similarly, non-speciﬁc
interactions between ribosomes or abundant free RPs with Mdm2
may occur in total cell lysates, where ribosomes can be partially
disintegrated. Indeed, a recent study showed that all tested RPs
coimmunoprecipitated with anti-Mdm2 antibodies from the total cell
lysate, including RPL5, RPL11, RPL23, RPL26 and RPS6 [53].
The observation that the depletion of either RPL5 or RPL11 abolishes
p53 upregulation in response to inhibition of rRNA transcription, rRNA
processing, import of RPs, and export of immature ribosomal subunits,
raises the question of the role of other Mdm2-binding RPs, which in
the absence of RPL5 and RPL11, would have been predicted to still
bind and inhibit Mdm2, upregulating levels of p53 [19,22,94]. The
depletion of either RPL5 or RPL11 inhibits ribosome biogenesis
[54,106]. However, this doesn't trigger the p53 response, probably
because RPL5 and RPL11 are essential transducers of p53-activating
signals upon ribosome biogenesis stress [19,22,53,54,94]. In contrast,
inhibition of ribosome biogenesis caused by the depletion of RPL23,
RPL26 and RPS7, like the depletion of other RPs, except for RPL11 and
RPL5, activates p53 in an RPL5- and RPL11-dependent manner [53,54].
Previously published studies showed that the depletion of RPS7
[100,101], RPL23 [55,96] or RPL26 [98] also compromises the induction
of p53 after pharmacological inhibition of ribosome biogenesis. Consis-
tent with the fact that the depletion of speciﬁc RPs can decrease the
number of ribosomes, a recent study showed that the inhibitory effects
of RPS7 and RPL23 depletion on p53 accumulation induced by actino-
mycin D may be attributed to effects on global translation, rather than
the loss of their speciﬁc effects on the Mdm2 function [54]. In fact, the
depletion of RPs that do not bind to Mdm2 (i.e. RPS6 and RPL7a) exerts
the same effect on actinomycin D-induced p53 accumulation [54].
Taken together, these observations highlight the centrality of RPL5
and RPL11 for p53 up-regulation in response to various ribosomal
stressors. Consistent with this, RPL5 and RPL11, but not RPL23, RPL26,
RPS3 and RPS7, accumulated in nonribosomal fractions upon various
impairments of ribosome biogenesis, where they interacted with
Mdm2 [53]. In addition to a number of cell culture studies, the RPL5–
RPL11–Mdm2–p53 pathway has been convincingly supported by an
in vivo mouse model. Knock-in mice that express a mutant Mdm2
(Mdm2C305F) that cannot bind RPL5 and RPL11 retain normal p53
response to DNA damage, but have impaired p53 activation upon
perturbations in ribosome biogenesis [30,94]. The differences between
these studies could also be due to time of treatment with pharmacolog-
ical inhibitors of ribosome biogenesis, siRNA sequences used, or cell-line
differences. Given that these early studies have convincingly shown that
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efﬁciently inhibit its ubiquitin protein ligase activity toward p53, there
is the possibility that they can regulate p53 levels in certain cell types
or upon speciﬁc impairments of ribosome biogenesis, or with kinetics
different from RPL5 and RPL11. Additionally, as previously shown for
nucleolar factor nucleostemin [50], RPS7, RPL23 and RPL26 and possibly
some other RPs may also trigger p53 activation when they are made
in excess independent of “ribosome biogenesis stress,” which may
occur in certain situations, as, for example, when c-Myc becomes
overexpressed [61].
Given technical difﬁculties in studying signaling functions of RPs as
mentioned above, it will be important to carefully design and interpret
the experiments before unambiguously ascribing a “p53-activating”
function to some of the previously suggested RPs or future candidate
RPs.
3.3. The source of ribosome-free RPL5 and RPL11 upon ribosome biogenesis
stress
Considerable controversy exists regarding the source of ribosome
stress-induced ribosome-free “p53-activating” RPs. During cell growth,Fig. 2. Three models explaining how p53 is upregulated upon ribosome biogenesis stress. (A)
subunits are imported into the nucleolus, where they assemble with rRNA. Mdm2 is free to
and passive diffusion of several RPs from the nucleolus to the nucleoplasm, where they intera
upregulation. (C) Upon speciﬁc impairment of 40S biogenesis the cell selectively upregulates
to the nucleus and interacts with Mdm2, leading to p53 upregulation. In contrast, inhibition o
are probably sufﬁcient levels of free RPL11 to bind to Mdm2 and inhibit the ubiquitin protein
RPL and RPS are normally synthesized but are degraded by nuclear 20S proteasomes. In contras
outside of the ribosomes in a complexwith 5S rRNA. This complex functions to inhibitMdm2-m
of the RPL5–RPL11–5S rRNA complex. A portion of the newly synthesized RPL5 and RPL11 co
ribosome biogenesis, suggesting that the altered nucleoli may provide a site for RPL5- and RP
into the nucleolus upon inhibition of ribosome biogenesis may also contribute to their accumuRPs are assembled into nascent ribosomes (Fig. 2A). Earlier work
suggested that perturbation of ribosome biogenesis causes nucleolar
disruption and passive diffusion of a number of RPs, including RPL5,
RPL11, RPL23, RPL26, and RPS7, from the nucleolus to the nucleoplasm,
where they bind to Mdm2 and inhibit its ubiquitin protein ligase func-
tion toward p53, leading to p53 upregulation [19,22,94] (Fig. 2B). Alter-
natively, one study proposed that upon overexpression of RPL11,Mdm2
enters the intact nucleolus to interact with unassembled RPL11 [91]. In
fact, others have shown that nucleolar disruption is not necessary to
activate p53 upon alteration of ribosome biogenesis [38,51]. Production
and nuclear import of RPs exceeding the needs of ribosome biogenesis
could be the only condition required to activate the p53 [38]. Indeed,
when 40S ribosome biogenesis is impaired, p53 is upregulated in an
RPL11-dependent manner, in the absence of any signiﬁcant effect on
60S ribosome biogenesis and nucleolar integrity [51] (Fig. 2C). Under
these conditions, the cell selectively upregulates the translation of a
group of mRNAs containing a 5′ terminal oligopyrimidine tract (5′
TOP) in the leader sequence, including the RPL11 mRNA [51,107]. The
overproduced RPL11 presumably translocates to the nucleus where it
interacts with and blocks the function of Mdm2, leading to p53 stabili-
zation (Fig. 2C). However, the molecular mechanism by which theUnder normal conditions, newly synthesized RPs of 40S (RPS) and 60S (RPL) ribosomal
degrade p53. (B) Conditions that inhibit ribosome biogenesis cause nucleolar disruption
ct with Mdm2 and inhibit its ubiquitin protein ligase activity toward p53, leading to p53
the translation of RP mRNAs, including the RPL11 mRNA. RPL11 presumably translocates
f 60S ribosome biogenesis impairs RPL11 mRNA translation. Under these conditions there
ligase function toward p53. (D) Upon impairment of ribosome biogenesis, the majority of
t, nascent RPL5 and RPL11 are mutually protected from degradation, and they accumulate
ediated p53 degradation. Additional stress-induced signalsmight also increase the stability
ntinues to accumulate in nucleoli together with Mdm2 and p53 even after inhibition of
L11-dependent p53 activation. Less efﬁcient import of nascent RPL5, RPL11 and 5S rRNA
lation outside of the ribosomes (indicated by red dashed arrow).
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be determined. In contrast, inhibition of 60S ribosome biogenesis
impairs RPL11 mRNA translation [51,107]. Under these conditions
there are probably sufﬁcient levels of free RPL11 to inhibit Mdm2 and
stabilize p53. Interestingly, upon concomitant inhibition of 40S and
60S ribosome biogenesis, induction of p53 is mediated by both of
these mechanisms, resulting in suprainduction of p53 [54].
A newmodel envisages that upon inhibition of ribosome biogenesis,
the majority of RPs are normally synthesized but are degraded by the
ubiquitin-independent proteasomal degradation to prevent potentially
toxic accumulation of unbound, free RPs in the cell [53,105,108–110]
(Fig. 2D). In contrast, nascent RPL5, RPL11 and 5S rRNA are redirected
from 60S ribosome biogenesis to Mdm2 inhibition in the cytoplasm
and the nucleoplasm upon disruption of ribosome biogenesis [53,106].
These three components of the ribosome have been shown to depend
on each other for Mdm2 binding and p53 induction [53,54,106]. It is
possible that the mutual protection from the ubiquitin-independent
proteasomal degradation and selective accumulation of ribosome-free
RPL5 and RPL11 upon impairment of ribosome biogenesis [53] depends
on the formation of the RPL5–RPL11–5S rRNA complex, which is under
such condition redirected from ribosomebiogenesis toMdm2 inhibition
[106] (Fig. 2D). Interestingly, the binding of ribosome-free RPL5 and
RPL11 to Mdm2 is not required for their accumulation under these
conditions [53,106]. The stability of the RPL5–RPL11–5S rRNA complex
may also be increased via their post-translational modiﬁcations or
binding to other factors under these conditions. However, no experi-
mental evidence exists in support of this prediction.
An important challenge for future investigation is to rigorously
validate thesemodels and uncover novel components of this checkpoint
signaling pathway and elucidate the molecular mechanisms of their
regulation.
3.4. Increasing complexity of the RP–Mdm2–p53 signaling pathway
A few new regulators of the RP–Mdm2–p53 signaling pathway have
recently emerged. Under normal conditions, the Mdm2–MdmX com-
plex represses the transcriptional activity of p53 and promotes its
polyubiquitination [70] (Fig. 3A). Interestingly, 5S rRNA bound to
MdmX in unstressed cells protects it from Mdm2-dependent
ubiquitination and degradation, contributing to p53 inhibition [111]Fig. 3.Mechanisms bywhichRPs regulate p53-dependent and -independent signaling pathways
5S rRNA complex represses the transcriptional activity of p53 aswell as polyubiquitinates p53. c
E2F-1 to promote cell cycle progression. (B) Upon inhibition of ribosome biogenesis, the RPL5–R
degradation and release of p53. Furthermore, ribosome-free RPL11 binds toMdm2 and inactiva
binds c-MycmRNA and there recruitsmiR-24/RISC to reduce the level of c-MycmRNA.Moreove
activator TRRAP to Pol I, Pol III and RP genes to inhibit ribosome biogenesis and cell growth.(Fig. 3A). As mentioned in Section 3.3., upon the impairment of ribo-
some biogenesis, the RPL5–RPL11–5S rRNA pre-ribosomal complex is
redirected from assembly into nascent 60S ribosomes toMdm2 binding
and inhibition of its E3 activity toward p53 [53,106,112]. Increased
binding of RPL11 to Mdm2, in addition to inhibiting Mdm2-mediated
degradation of p53, facilitates Mdm2-dependent MdmX ubiquitination
and degradation, thus allowing full activation of p53 [111,113] (Fig. 3B).
These results suggest that 5S rRNA may act as a positive or negative
regulator of p53 depending on its association with the RPL5–RPL11–
Mdm2 complex or MdmX, respectively. A recent study showed that
RPS15, RPS20 and RPL37, in addition to inhibiting Mdm2-mediated
degradation of p53, can downregulateMdmX levels but via distinctmo-
lecularmechanisms. RPS15 and RPS20 directly interact withMdmX and
downregulate its protein levels, whereas RPL37 downregulates the
MdmX mRNA levels [60]. Taken together, these results add to the
complexity of the RP–Mdm2–MdmX–p53 network.
In yeast, two assembly factors, Rpf2 and Rrs1, are essential for
assembling the RPL5–RPL11–5S rRNA complex into pre-ribosomes
[114]. It was recently shown that their human homologues, hRrs1 and
Bxdc1, are not essential components of the ribosome-free RPL5–
RPL11–5S rRNA complex which regulates Mdm2 upon inhibition of
ribosome biogenesis in human cells, suggesting that they lie at, or
downstream of, the regulatory branch point that mediates the targeting
of the RPL5–RPL11–5S rRNA precursor complex to inhibition of Mdm2
[106].
A new study suggests that PICT1 (protein interacting with the C
terminus 1 of the tumor suppressor PTEN), also known as GLTSCR2
(glioma tumor suppressor candidate region 2 gene), is a negative
regulator of RPL11-mediated p53 activation [115]. It was originally
proposed that PICT1 is a tumor suppressor because it stabilizes phos-
phatase and tensin homolog (PTEN) [116] and its low expression in
diffuse glioma and ovarian cancer is correlated with a more aggressive
phenotype [116–118]. However, more recent studies suggested that
PICT1maynot be a tumor suppressor. Patientswith oligodendrogliomas
with PICT1-haploinsufﬁciency have a better prognosis than other
oligodendroglioma patients [119–121]. Similarly, colon and esophageal
cancer patients whose tumors retain wild-type p53 lower expression of
PICT1 appear to have a better prognosis [115]. Also, PICT1-heterozygous
mice are more resistant to develop a chemically-induced papillomas
compared to wild-type mice [115]. Consistent with these effects, theupon ribosomebiogenesis dysfunction. (A) Under normal conditions, theMdm2–MdmX–
-Myc promotes cell growth by upregulating ribosome biogenesis, whereasMdm2 stabilize
PL11–5S rRNA complex binds to theMdm2–MdmX–5S rRNA complex, leading to its auto-
tes its E2F-1 stabilizing function, leading to a p53-independent cell cycle arrest. RPL11 also
r, ribosome-free RPL11 binds to c-Myc and blocks the recruitment of its transcriptional co-
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cally, PICT1 binds to and retains RPL11 in the nucleolus and its deletion
allows the release of RPL11 to the nucleoplasm,where it binds toMdm2
and blocks Mdm2-mediated ubiquitination [115]. Interestingly, it was
suggested that RPL11 acts in an RPL5-independent manner under
these conditions [115], contradicting the model in which RPL5 and
RPL11 are mutually dependent in p53 activation [53,54,112,115].
NEDDylation is the process by which the ubiquitin like protein
NEDD8 is conjugated to its target proteins. Recently, NEDDylation of
RPL11 has been implicated in p53 stabilization and its transcriptional
activation in response to inhibition of ribosomebiogenesis by actinomy-
cin D. In the absence of ribosome biogenesis stress, NEDDylation of
RPL11 protects it from degradation and is required for its localization
in the nucleolus [122]. However, actinomycin D treatment triggers a
rapid RPL11 de-NEDDylation, thus causing its re-localization to the nu-
cleoplasm, where it binds Mdm2. It was also suggested that Mdm2-
mediated NEDDylation protects RPL11 from degradation in the nucleus,
allowing Mdm2-mediated p53 stabilization upon actinomycin D treat-
ment [122]. These ﬁndings are in contrast with two recent studies that
showed accumulation of ribosome-free RPL11 upon actinomycin D
treatment occurred even in the absence of Mdm2 and p53 [53,106].
This discrepancy certainly requires further investigation.
It is known that impairment of ribosome biogenesis by low dose ac-
tinomycin D treatment triggers p300/CBP-mediated p53 acetylation,
which plays a role in the regulation of p53 stability and enhancement
of p53-mediated transcription [123]. Mahata and coworkers showed
that upon actinomycin D treatment NEDDylated RPL11 is rapidly but
transiently recruited to promoter sites of p53 target genes in an
Mmd2-dependent manner [124]. The binding of NEDDylated RPL11 re-
lieves p53 fromMdm2-mediated transcriptional repression, suggesting
yet another important level of p53 regulation by RPL11 [124].
Very recently, additional insights into regulation of p53 transcrip-
tional activity in response to inhibition of ribosome biogenesis were ob-
tained. Myb-binding protein 1a (MYBBP1A), which is localized in the
nucleolus in an RNA-dependent manner, translocates to the nucleo-
plasm upon impairment of ribosome biogenesis [125]. This transloca-
tion is dependent on RPL5 and RPL11, and increase the interaction
between p53 and p300/CBP to enhance p53 acetylation. Additionally,
the promyelocytic leukemia (PML) tumor suppressor was implicated
in regulating p53 acetylation on residue K382 upon low-dose actinomy-
cin D treatment [123,126]. It was reported that PML co-localizes with
p53, acetylated-p53 and Mdm2 in the disrupted nucleoli upon actino-
mycin D treatment in RPL5- and RPL11-dependent manner [53], imply-
ing a role for the nucleolus in p53 acetylation by ribosome biogenesis
stress.
In conclusion, understanding the molecular mechanisms by which
ribosome biogenesis stress regulates p53 acetylation and its transcrip-
tional activation, as well as assessing the biological relevance of post-
translational modiﬁcations require further investigation.4. p53-Independent signaling pathways downstream of RP–Mdm2
checkpoint activation by ribosome biogenesis dysfunction
Several studies reported the existence of p53-independent response
pathways to impaired ribosome biogenesis [127]. Here wewill focus on
those involving common players of the canonical RP–Mdm2 pathway.
Since growing evidence argues for p53-independent effects of Mdm2
in various biological processes including cell cycle control, apoptosis,
differentiation, epithelial-to-mesenchymal transition, DNA repair, tran-
scription, and other processes, the possibility exists that RPL5 and RPL11
may also inﬂuence these Mdm2 functions upon inhibition of ribosome
biogenesis [128,129]. It has been demonstrated that impairment of
rRNA transcription in cells with inactivated p53 results in inhibition of
cell cycle progression via down-regulation of the transcription factor
E2F-1. Mechanistically, RPL11 interacted with Mdm2 and inactivatedits E2F-1-stabilizing function under these conditions [130] (Fig. 3A
and B).
It is possible that RPL11 may, in addition to Mdm2, bind to
other partners upon ribosome biogenesis stress, thus expanding the
repertoire of cellular biological processes it regulates. Under normal
conditions c-Myc promotes cell growth by upregulating ribosome bio-
genesis (Fig. 3A) [4,131,132]. Itwas shown recently that upon inhibition
of ribosome biogenesis RPL11 binds c-Myc mRNA at its 3′ untranslated
region (3′-UTR) and recruits micro-RNA-induced silencing complex
(miRISC) and miR-24, leading to c-Myc mRNA degradation [133]
(Fig. 3B). Under the same conditions, RPL11 also binds to the N-
terminal transcriptional activation domain of c-Myc and inhibits the re-
cruitment of its transcriptional coactivator, transformation/transcrip-
tion domain-associated protein (TRRAP), at the promoters of its target
genes driven by Pol I, Pol II or Pol III [61,134,135]. By down-regulating
c-Myc expression and transactivation activity RPL11 inhibits ribosome
biogenesis and cell growth upon ribosome biogenesis stress (Fig. 3B).
A systematic approach for identifying direct and indirect RPL5 and
RPL11 protein and RNA partners will be required to explore the full
complexity of this novel and important signaling pathway. Potential
linkages of RPL5 and RPL11 with characterized proteins and RNAs may
suggest novel biological functions of RPL5 and RPL11 in response to
defects in ribosome biogenesis.5. Quality control of ribosome biogenesis and degradation of
defective ribosomes
The mechanisms by which various defects in ribosome biogenesis
trigger p53-dependent and -independent biological responses, which
probably allow adaptation of the cell to ribosome biogenesis stress,
have been intensively studied in mammalian cells [22]. However, little
is known about quality controlmechanisms that prevent defective ribo-
somes from accumulating and generating translational errors and com-
peting with functional ribosomes for amino acids, translation factors,
and mRNAs [136,137]. A failure to properly recognize and degrade
such defective ribosomes could also have deleterious consequences be-
yond themRNA translation. For example, unassembled rRNAprecursors
could inappropriately interact with rDNA, leading to the formation of
rRNA–rDNA hybrids, which may be a source of DSB and genomic insta-
bility [138,139], as well as alter normal functions of the nucleolus in
various biological processes [140]. Upon impairment of ribosome bio-
genesis, it appears that there might be nuclear quality control processes
in place to monitor aberrant pre-ribosomal assembly. Such defective
ribosome intermediates can be prevented from exiting the nucleolus
[9,141], where they are degraded by a process involving the Trf4/5,
Air1, Mtr4 polyadenylation (TRAMP) complex. The TRAMP complex
polyadenylates defective or naked rRNA substrates in nucleolar struc-
ture termed the No-body, thus triggering their exosome-mediated
degradation [142].
In addition to surveillance of aberrant pre-ribosomal assembly that
occurs in the nucleolus, there might be quality control for mature ribo-
somes. Mature 40S and 60S ribosomes are monitored by nonfunctional
rRNA decay (NDR) [143,144]. However, it appears that there are mech-
anistically distinct NDR pathways involved in turnover of 40S or 60S
ribosomal subunits. In contrast to 40S subunits, it has been shown
that nonfunctional 60S ribosomes are subjected to active ubiquitin-
dependent degradation, which requires the ubiquitin protein ligase
component Rtt101p and its associated protein Mms1p [143]. RP or
other proteins associated with nonfunctional ribosome particles are
ubiquinated and degraded in an Rtt101p–Mms1p-dependent manner.
Upon degradation of these proteins, naked nonfunctional rRNA is
exposed to RNases and digested [143].
Finally, mature ribosomes are degraded by a speciﬁc type of autoph-
agy, termed ribophagy, upon nutrient starvation [145]. This process
requires the deubiquitination enzymes Bre5 and Ubp3 [145]. It remains
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mechanism able to remove unassembled or damaged ribosomes.
All these mechanisms were discovered in yeast, and similar mecha-
nisms of ribosome biogenesis quality control operating in mammalian
cells have yet to be uncovered. It will be of paramount importance to
characterize the mechanisms by which a quality control system senses
defects in ribosome biogenesis and to elucidate their relationship with
the RP–Mdm2–p53 checkpoint signaling pathway. It can be hypothe-
sized that the RP–Mdm2–p53 cell cycle checkpoint creates an extended
timewindow to allow completion of removal of lesion in ribosome bio-
genesis prior cell division. Additionally, ribosome-free RPL11 and acti-
vated p53 could block various aspects of ribosome biogenesis by
inhibiting c-Myc [50,131,133,134] or directly repressing Pol I and Pol
III activities, import of RPs and export of ribosomal subunits respective-
ly, until lesions in ribosome biogenesis are removed [61,146]. Given the
role of p53 in the regulation of autophagy [147,148], itwould be exciting
to test the possibility that p53 regulates ribophagy upon ribosome bio-
genesis stress. There is abundant room for further progress in these
areas of research.
6. Communication of the ribosome biogenesis stress signaling
pathway with the DNA damage response, oncogenic signaling and
splicing machinery
Although extensive evidence has been accumulated over the past
decade that shows perturbation of ribosome biogenesis in the nucleolus
can trigger p53 stabilization and activation independent of DNAdamage
and ARF via binding of several RPs to Mmd2 and inhibition of its E3 ac-
tivity toward p53 [22,30,34], a number of studies strongly point to the
fact that both DDR and ARF can inhibit ribosome biogenesis, and conse-
quently engage several RPs in p53 activation (Fig. 4). Rubbi and MilnerFig. 4. Interplay between theDDR andARFwith the RP–Mdm2–p53 signaling pathway. Both
DNA damage and oncogenes trigger the DDR. The stabilization and activation of p53 in re-
sponse to DNA damage result from phosphorylations of p53 and Mdm2 that disrupt their
interaction. Oncogenic stress also upregulates ARF, which binds to Mdm2 and inhibits its
activities toward p53. Both the DDR and ARF inhibit Pol I transcription. Additionally, the
DDR and ARF inhibit rRNA processing via degradation of RPL37 or NPM1/B23, respectively.
The resulting ribosome biogenesis stress presumably triggers the RP–Mdm2–p53 signaling
pathway (dashed arrow) and leads to the accumulation of ribosome-free RPL26. The inhibi-
tory effect of Mdm2 on RPL26 is attenuated by the DDR, enabling its binding to p53 mRNA
and its rapid translation. The relative contribution of the ribosome biogenesis stress signaling
to p53 activation by the DDR and ARF remains to be elucidated.ﬁrst proposed the idea that most p53-inducing genotoxic stressors also
inhibit ribosome biogenesis and compromise the structure of the nucle-
olus [37] (Fig. 4). They suggested that nucleolar disruptionwas required
for induction of p53 in response to DNA damage, as induction of DNA
damage without nucleolar disruption did not trigger p53 [37]. The re-
petitive nature of the rDNA region and the high rate of Pol I transcrip-
tion, makes rDNA highly unstable. Thus, it has been proposed to act as
a potential sensor for DNA damage [149]. UV-mediated DNA damage
causes nucleolar disruption by directly inhibiting rDNA transcription
as well as by global RNA Pol II transcription [37,89,150], whereas DSB
lead to a transient repression of rDNA transcription via ATM–NBS1–
MDC1-dependent interference with Pol I initiation complex assembly,
which results in a premature displacement of elongating holoenzymes
from rDNA [151]. But how do these nucleolar changes contribute to
p53 activation upon DNA damage? It was originally suggested that
impairments of nucleolar structure and function abrogate Mdm2-
mediated p53 polyubiquitilation in the nucleolus and its consequent
proteasomal degradation, leading to p53 accumulation [37,152]. More
evidence suggests that nucleolar disruption associated with DNA dam-
aging stressors engages the aforementioned RP–Mdm2–p53 signaling
pathway as well as other RP-dependent signaling pathways to boost
the p53 response [22]. It was ﬁrst shown that RPS7 and RPL11 are re-
quired for full p53 stabilization and activation in response to DNA dam-
age [101,153]. Recently, Llanos and co-workers [57] uncovered an
interesting mechanism by which RPL11 is engaged in p53 activation
by DNAdamage (Fig. 4). Treatment with cisplatin, UV light or doxorubi-
cin decreased the level of RPL37, which caused ribosome biogenesis
stress and consequently activation of the RPL11–Mdm2–p53 signaling
pathway. Further research will be required to elucidate the underlying
mechanism by which DNA damage leads to RPL37 degradation and de-
termines whether this regulation is speciﬁc to RPL37 or is general to
other RPs. In addition to RPL11 and RPS7, RPS3 was shown to trigger
p53 stabilization in response to oxidative stress and associated DNA
damage by interacting with both Mdm2 and p53 [99]. RPL26 was also
shown to be a positive regulator of p53 at the translational level upon
γ-irradiation (Fig. 4). Under these conditions RPL26 competes with
the nucleolin homodimers for binding to both the 5′- and 3′-UTRs of
p53mRNAand consequently stimulates its translation [154–156]. How-
ever, the source of p53 mRNA-interacting RPL26 upon DNA damage
remains to be determined. Under non-stressed conditions, Mdm2
inhibits RPL26 interaction with p53 mRNA as well as targeting it for
degradation. In response to genotoxic stress, the inhibitory effect of
Mdm2 on RPL26 is attenuated, enabling its binding to p53 mRNA and
a rapid increase in p53 synthesis [97]. In addition to upregulation of
p53 via its direct binding to Mdm2 [64,85], ARF can also suppress ribo-
some biogenesis at multiple levels upon oncogenic signaling (Fig. 4).
First, ARF inhibits rRNA processing by binding to NPM1/B23 and medi-
ating its degradation [157,158]. Second, it interfereswith Pol I transcrip-
tion by blocking UBF1 (upstream binding factor 1) phosphorylation or
preventing the nucleolar import of TTF-1 (transcription termination
factor 1) [159,160]. Third, ARF inhibits 5S rRNA synthesis by blocking
Pol III transcriptional activity [161]. Consequently, ARF-mediated inhibi-
tion of ribosome biogenesis might activate the RP/5S rRNA–Mdm2–p53
pathway (Fig. 4). In support of this model, overexpression of ARF
increased the levels of ribosome-free RPL11 [162]. In addition to this
mechanism, oncogenic c-Myc can also trigger the RP–Mdm2–p53 path-
way independent of ARF- or DNA damage-mediated ribosome biogene-
sis stress, probably by upregulating synthesis of RPs, which bind to
Mdm2 and augment cellular p53 activity [30,61]. Recent overexpression
experiments in cell culture showed that ARF and RPL11 cooperatively
bind to Mdm2 and inhibit its ubiquitin protein ligase activity toward
p53 [162]. Together, these observations suggest that the physical
and functional interplay between the RPL5–RPL11–Mdm2–p53, ARF–
Mdm2–p53 and DDR signaling pathways may provide an important
anti-cancer barrier. However, the detailed molecular mechanisms
whereby these signaling pathways communicate with each other
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activation and tumor suppression remain to be elucidated.
Splicing is a highly regulated step of gene expression. Alteration in
this process can have deleterious consequences on the cell. It was
recently shown that oncogenic serine/arginine-rich splicing factor 1
(SRSF1), which is overexpressed in many cancers, binds the RPL5–
Mdm2 complex and stabilizes the tumor suppressor p53 [163]. This
observation suggests that a p53-dependent ribosome biogenesis stress
signaling pathway may also sense the inﬁdelity of splicing to trigger
p53-dependent cellular adaptation mechanisms, even though the
authors did not clarify whether RPL5 is causative, or only permissive
for this response [163]. It would also be important to determine the
effect of RPL11 depletion in this model, given its essential role in p53
upregulation by the RP–Mdm2 checkpoint.
7. Role of aberrant upregulation of p53 in the pathogenesis
of ribosomopathies
Based on concepts developed in the above-mentioned studies of
mouse models of RP-insufﬁciencies, it was suggested that p53 could
also be involved in mediating some of the phenotypic manifestations
of human ribosomopathies, a diverse group of pathological conditions
in which genetic abnormalities cause defective ribosome biogenesis
and/or mature ribosome function [33]. Indeed, recent studies of
mouse models of human ribosomopathies or patients with ribo-
somopathies point to a causative role of aberrant p53 upregulation in
the pathogenesis of Treacher Collins syndrome (TCS), Diamond–
Blackfan anemia (DBA), 5q-syndrome and possibly Shwachman–
Diamond syndrome (SBDS).
7.1. Evidence from mouse models of ribosomopathies
TCS is an autosomal dominant disorder of human craniofacial devel-
opment that results from loss-of-function mutations in the TCOF1 gene
[164], which encodes treacle protein that participates in rDNA tran-
scription and rRNA modiﬁcation during the early stages of processing
[165,166]. The ﬁrst strong indication that p53 plays a role in the patho-
genesis of human ribosomopathies came from studies of Tcof1-
heterozygous mice that accurately recapitulate human TCS [167].
Haploinsufﬁciency of Tcof1 in these mice perturbs ribosome biogenesis,
and consequently triggers p53-mediated apoptosis in neuroepithelial
and neural crest cells [167]. Genetic and pharmacologic inhibition of
p53 prevented apoptotic elimination of neural crest cells and fully
rescued the craniofacial abnormalities in Tcof1-heterozygous mice
[167], showing that aberrant p53 upregulation is the underlying cause
of TCS.
Heterozygous mutations or deletions of RP genes have been impli-
cated in the pathogenesis of two bone marrow failure syndromes in
humans, DBA and the 5q-syndrome, a subtype of myelodisplastic
syndrome (MDS) [33]. DBA is a congenital disease characterized by
macrocytic anemia with decreased erythroid progenitors in the bone
marrow. About half of affected individuals also have craniofacial and
thumb malformations, anomalies of the heart and urogenital system
aswell as short stature. DBA patients have an increased risk of develop-
ing acute myeloid leukemia (AML) and solid malignancies [28]. In
addition to RPS19, the ﬁrst identiﬁed and the most frequent mutations
in DBA [16], pathogenic mutations or deletions of other RP genes,
including RPL5, RPL11, RPS26, RPL35A, RPS7, RPS10, RPS17, RPL26,
RPS24 and RPL15 have been recently identiﬁed in about 50–60% of
patients [168–180]. Interestingly, there are correlations between specif-
ic gene defects and the presence and type of congenital malformations.
Mutations in RPL5 and RPL11 are associated with a higher overall
frequency of occurrence of congenital malformations than in other
DBA patients [169,171,176]. Furthermore, mutations in the RPL5 gene
are associated with a higher frequency of craniofacial abnormalities
and mutations in RPL11 with thumb malformations [169,171,176].Deﬁciencies of any of mutated RP genes in DBA are associated with ab-
normal ribosome biogenesis within affected tissues of these patients,
suggesting that a deﬁcit of functional ribosomes is responsible for the
pathological manifestations [15,181–184].
Several mouse and zebraﬁsh models of DBA have been generated,
which show overlapping and nonoverlapping phenotypes. Unfortu-
nately, none of them fully recapitulate phenotypic features observed
in DBA patients. These differences between these mouse models and
DBA patients could reﬂect the inﬂuence of polymorphisms in genes dis-
crete from the primarymutations or species-speciﬁc differences. Homo-
zygous deletion of RpS19, the most commonly mutated gene in DBA, is
lethal in mice at the early embryo stage [185]. However, heterozygous
embryos develop normally, showing no feature of the human DBA syn-
drome later in life [185]. Subsequently, in a large scale mutagenesis
screen in mice for pigmentation abnormalities, Dark skin 3 (Dsk3) mu-
tant was isolated carrying heterozygous missense mutation (T316A) in
Rps19 [32]. Interestingly patients with DBA do not show pigmentation
abnormalities [33]. As has been described in humans with DBA,
Rps19Dsk3 mice also displayed macrocytic anemia with decreased ery-
throid progenitors in the bone marrow and reduced body size. Pheno-
typical differences between these mice and the ones used by Matsson
and colleagues [185] could be due to the different genetic background,
or to a partial negative dominance of themutated protein. Genetic inac-
tivation of p53 in Rps19Dsk3 mice rescued the erythrocyte and body
weight phenotypes as well as the pigmentation phenotypes [32]. Hy-
perpigmentation was traced to p53-dependent upregulation of the Kit
ligand in keratinocytes, which then stimulatedmelanocyte proliferation
via a paracrinemechanism [32]. Consistent with thismouse DBAmodel,
p53was shown tomediate DBA-like hematopoietic defects in transgen-
ic mice expressing shRNA against Rps19 under the control of an induc-
ible promoter [186]. The involvement of p53 in DBA was further
supported by the rescue of various developmental abnormalities in
rps19-deﬁcient zebraﬁsh upon suppression of p53 and its family mem-
ber, deltaNp63 [187]. However, knockdown of p53 did not alleviate ery-
throid aplasia in rps19-deﬁcient zebraﬁsh, suggesting the existence of a
p53-independent but rps19-dependent pathway that is responsible for
defective erythropoiesis in this DBAmodel [188]. This differential role of
p53 in the erythropoietic phenotypes of Rps19-deﬁcient mice and
zebraﬁsh remains to be elucidated [32,188]. Recently, twomousemuta-
tions of Rps7 (Rps7Mtu and Rps7Zma), a gene that has been implicated in
DBA,were found in anN-ethyl-N-nitrosoureamutagenesis screen [189].
In contrast to DBA patients, Rps7Mtu/+ and Rps7Zma/+ mutant mice do
not display anemia [189]. They are characterized by reduced body
size, abnormal skeletal morphology and mid-ventral white spotting,
the phenotypes sharedwith some other RP-deﬁcient mice [31,189]. Ad-
ditionally, increased neuronal apoptosis leads to malformations of the
developing central nervous system and defects in working memory,
the phenotypes not seen in other RP-deﬁcient mice or DBA patients
[189]. Interestingly, they show a decreased viability, which tends to be
highly variable, depending on genetic background. Inactivation of one
p53 allele largely rescued all morphological phenotypes of these mice
and promoted their survival. Thus, p53 mediates both hematopoietic
and non-hematopoietic phenotypes in these mouse and zebraﬁsh DBA
models, strongly suggesting that it may also play an important role in
the pathogenesis of DBA [189].
The 5q-syndrome is caused by a somatically acquired deletion in the
long arm of chromosome 5, and is characterized by macrocytic anemia
with decreased erythroid progenitors in the bone marrow and an in-
creased risk of developing AML, similar to DBA. Additionally, these
patients present with thrombocytosis and megakaryocytic dysplasia
[33]. On the basis of a small scale RNAi screen targeting 40 genes in
the common deleted region (CDR) of the 5q-syndrome, RPS14 was
identiﬁed as a critical gene on 5qwhose hemizygosity recapitulates ery-
throid abnormalities in 5q-MDS, a phenotype that was rescued in vitro
by forced expression of RPS14 in hematopoietic stem cells from the
5q-patients [190,191]. Recently a mouse model of the human 5q-
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mediated heterozygous deletion of a region of chromosome 18,which is
syntenic for the CD74–Nid67 interval of the CDR that contains eight
genes, including Rps14 [192]. These mice developed macrocytic anemia
and monolobulated megacaryocytes, and their bone marrow progeni-
tors show aberrant expression of p53 and signs of apoptosis. p53 deﬁ-
ciency in these mice ameliorated the macrocytic anemia, which is
caused by Rps14-haploinsufﬁciency, suggesting an important role of
the p53 responses in the pathogenesis of the 5q-syndrome [192]. Re-
cently, a deﬁciency in the expression of two microRNAs that are tran-
scribed from the CDR of the 5q-syndrome, miR-145 and miR-146a, has
been shown in mice to contribute to thrombocytosis, megakaryocytic
dysplasia and the increased risk of AML, but not the macrocytic anemia
[193].
Shwachman–Diamond syndrome (SDS) is an autosomal recessive
disorder characterized by exocrine pancreatic insufﬁciency, skeletal de-
fects, chronic neutropenia and a propensity to develop MDS and AML
[33]. Approximately 90% of SDS patients have been found to have bi-
allelic mutations in the SDBS gene, whose product facilitates the release
of eIF6, a factor that prevents joining of the 60S and 40S subunits into
80S ribosomes [194–196]. Knockdown of the zebraﬁsh sdbs ortholog
produces a phenotype resembling SDS patient pathology [197]. Where-
as loss of p53 rescued the skeletal phenotype of sdbs-deﬁcient zebraﬁsh,
it did not rescue the pancreatic defect and neutrophil deﬁciency [197].
Interestingly, knockdown of sdbs gene resulted in aberrant expression
of genes involved in ribosome biogenesis in the pancreas, including
rpl3 and pescadillo. Knockdown or mutation of either rpl3 or pescadillo
recapitulated p53-independent effects of sdbs knockdown on the pan-
creatic development [197].
7.2. Evidence from patients with ribosomophaties
Consistent with studies on animal models of human disorders of
defective ribosome biogenesis described above, mounting evidence
suggests that activation of p53 may also underlie the pathogenesis of
the human DBA, 5q-syndrome and Shwachman Diamond syndrome
(SDS). The depletion of RPS14 or RPS19 by short harpin (sh) RNA in
human CD34+ hematopoietic progenitor cells led to induction of p53
and a p53-dependent cell cycle arrest and apoptosis in erythroid pro-
genitor cells, suggesting a role for p53 in the pathogenesis of the 5q-
MDS and DBA patients [58,198]. Importantly, accumulation of nuclear
p53was found in bonemarrowbiopsy samples fromDBA, 5q-syndrome
and SDS patients, suggesting the basis for the failure of erythropoiesis in
these diseases [58,199,200].
It was surprising that p53 was also upregulated in primary hemato-
poietic progenitor cells from DBA patients with mutations in RPL11 or
the same cells from control subjects after the depletion of RPL11 with
shRNA, given that numerous cell culture experiments demonstrated
that RPL11 is a critical positive regulator of p53 upon impairment of ri-
bosome biogenesis [19,22,94]. These results suggest that RPL11 levels
may be sufﬁcient in these hematopoietic progenitor cells to trigger the
p53 response [198]. Another possibility is that, in contrast to cell culture
models [19,22,94], RPL11-deﬁciency may activate a p53-dependent
checkpoint response, as previously observed in rpl11-deﬁcient zebraﬁsh
[201]. Further studies of p53 in DBA, 5q-syndrome and SDS patients
may provide insights into pathogenesis, not only of defective erythro-
poiesis, but also other developmental abnormalities and the cancer pre-
disposition that are inherent to these diseases, as well as guide the
development of new therapeutic approaches for ribosomophaties.
7.3. How does p53 contribute to tissue-speciﬁc pathological manifestations
of ribosomophaties?
Mutations affecting components involved in ribosome biogenesis
may result in decreased ribosome number or aberrant ribosomes,
which can deregulate gene expression at the level of translation. Almost40 years ago, Harvey Lodish postulated that the spectrum of translated
mRNA varies with the overall number of ribosomes [202]. Messenger
RNAs that have low afﬁnity for translational machinery are out-
competed with messages with high afﬁnity when the number of ri-
bosomes is reduced, whereas low and high-afﬁnity mRNAs are
translated when ribosome biogenesis is upregulated [203,204]. Thus,
it is reasonable to assume that speciﬁc mutations that lead to a reduced
number of functional ribosomes to mRNA transcripts in the cell would
alter not only the rate of total protein synthesis, but also the patterns
of translated mRNAs [205]. Furthermore, qualitative defects in ribo-
some biogenesis might affect the translation of speciﬁc target mRNAs
[206–208]. Moreover, recent studies have suggested that some factors
involved in ribosome biogenesis may participate in other important
cellular functions [146,209]. However, the contribution of these pro-
cesses to the pathological phenotypes of ribosomopathies will not be
discussed here.
How can p53 be responsible for tissue-speciﬁc pathologicalmanifes-
tations in ribosomopathies? A possibility exists that tissue-speciﬁc up-
regulation of p53 in response to inherited mutations in a component
involved in ribosome biogenesis may be caused by tissue-speciﬁc de-
fects in ribosome biogenesis. For example, the same mutation may
allow normal ribosome production in tissues where rates of ribosome
biogenesis, cell growth, and cell division are slow but not in highly pro-
liferating tissues that require intense ribosome production [31,34].
Moreover, the extent bywhichmutation in a component involved in ri-
bosome biogenesis will lead to inhibition of ribosome biogenesis, and
consequently p53 upregulation, might also depend on the relative
expression levels of that component in speciﬁc tissues, its require-
ment in ribosome biogenesis or the severity of the mutant allele
[14,15,32,33,189]. Furthermore, other factors can determine whether
or not this potential for rapid overproduction and accumulation of p53
in response to a deﬁciency in ribosome biogenesis can actually occur.
Such factors could be expression levels of p53 mRNA or its upstream
regulators in speciﬁc tissues or developmental stages as well as the ge-
netic background of an affected individual [4,189,210].
p53 responses in speciﬁc tissues can dependon the expression levels
of its target genes. For example, in response to a RP deﬁciency p53
down-regulates white spotting gene Kit in developing melanocytes,
whereas in keratinocytes it upregulates the expression if Kit ligand
(KITL), leading to skin hypopigmentation or hyperpigmentation, re-
spectively [32].
Relatively little is known about p53 downstream targets in mouse
models of ribosomopathies and in human patients. Gene expression
proﬁling in Rpl24Bst/+ mouse embryos and CD34+ hematopoietic stem
cells from patients with the 5q-syndrome identiﬁed a number of over-
lapping and non-overlapping p53 target genes that are signiﬁcantly
deregulated, including those involved in apoptosis (FAS, TRAF1, CASP3,
BAX, BID, cyclin G and DR5), cell cycle regulation (CDKN1a), stress re-
sponses (SESN2, SESN3 andWIG1), mTORC1 signaling (SESN2), autoph-
agy (SESN2), DNA damage repair (DDB2), metastasis suppression
(CD82) and p53 regulation (MDMX and PARC) [31,200]. However, fur-
ther research is ultimately needed to identify additional p53 target
genes that are deregulated upon impairment of ribosome biogenesis
in vivo and understand the molecular links between these targets and
tissue-speciﬁc phenotypes.
8. The role of the RPL5–RPL11–Mdm2–p53 signaling pathway in
malignant transformation and tumor progression
It is well established that upregulation of translational capacity as a
result of increased ribosome biogenesis contributes to cancer develop-
ment and progression [211–213]. Recent evidence suggests that the
RPL5–RPL11–Mdm2–p53 pathway may monitor excessive ribosome
biogenesis to prevent tumorigenesis. One of the key regulators of ribo-
some biogenesis is c-Myc, which upregulates transcription of 47S
rRNA, 5S rRNA, and all RPs [4,61,131,214]. In an attempt to assess the
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lymphomas overexpressing c-Myc under the control of the immuno-
globulin heavy chain promoter and enhancer (Eμ-Myc), Barna and co-
workers crossed Eμ-Myc transgenic mice onto a Rpl24-heterozygous
genetic background [215]. The onset of B-cell lymphoma in these mice
was delayed. One explanation for this could be the re-normalization of
protein synthetic rate as a result of inability of c-Myc to upregulate
nascent ribosome biogenesis due to a limiting amount of Rpl24. Howev-
er, given the fact that RPL24-deﬁciency triggers the RP–Mdm2–p53
signaling pathway [31], this mechanism might also be responsible for
the delayed onset of B-cell lymphoma in these compoundmice. Alterna-
tively, the accumulation of free RPL11 upon Rpl24-haploinsufﬁciency
may repress c-Myc's transcriptional activity by directly binding to
it [134,135] or through a mir-24/miRISC-mediated mechanism
[133–135]. The most convincing evidence yet that the RPL5–
RPL11–Mdm2–p53 signaling pathwaymonitors the excessive ribosome
biogenesis to inhibit tumorigenesis was provided recently by Macias
and co-workers [30]. They showed that loss of the RPL5–RPL11–
Mdm2 interaction in knock-in mice that express the mutant
Mdm2C305F signiﬁcantly reduced the p53 levels and accelerated Eμ-
Myc-induced B-cell lymphomagenesis. The results of this study also
supported a model in which the RP5–RPL11–Mdm2–p53 and the
ARF–Mdm2–p53 pathways are independent, parallel pathways work-
ing together to protect cells from Eμ-Myc-induced tumorigenesis [30].
Even though this is an important step forward in understanding the
roles of RPL5 and RPL11 in tumorigenesis, we must be aware of certain
limitations of this model. The Mdm2C305F mutation may affect Mdm2's
functions that are independent of RPL5–RPL11 binding, such as interac-
tions with other regulatory or target partners. In contrast to Eμ-Myc-
induced B-cell lymphomagenesis [30], the disruption of the RPL5–
RPL11–Mdm2–p53 signaling by an Mdm2C305F mutation did not
accelerate prostatic tumorigenesis in a model in which the RB family
members pRB/p107/p130 were inactivated [216]. These results suggest
that RPL5–RPL11-mediated regulation of p53 is not essential for inhibi-
tion of tumorigenesis in this model. However, it remains to be deter-
mined whether inactivation of RB family members triggers the
nucleolar stress response that results in accumulation of ribosome-
free RPL5 and RPL11. Furthermore, the possibility exists that RPL5 and
RPL11 may play a role in tumorigenesis independent of the Mdm2–
p53 module.
The observations that patients with ribosomopathies have a higher
incidence ofmalignancies and that heterozygousmutations of a number
of RPs in Drosophila and zebraﬁsh result in benign or malignant tumors
strongly suggest that defective ribosome biogenesis may be an onco-
genic event [28,217–219]. This is most likely related to quantitative or
qualitative defects in mRNA translation, although mechanisms that are
unrelated to protein synthesis can't be excluded. Since errors in ribo-
some biogenesis are frequently associated with activation of the RP–
Mdm2–p53 signaling pathway, it can be speculated that induction of
this response prevents expansion of such potentially hazardous cells.
Studies in RP-deﬁcient zebraﬁsh provided some evidence in support of
that speculation. Deﬁciencies of 17 individual RPs in zebraﬁsh lead to
the development of very raremalignant peripheral nerve sheath tumors
(MPNST) [219]. It has been suggested that the lesion in translation in
these zebraﬁsh mutants acts as an initiation event for cancer [27]. Sur-
prisingly, MPNST were frequently observed in zebraﬁsh carrying
inactivating mutations of p53 [220]. Subsequent work showed that
RP-haploinsufﬁcient zebraﬁsh cells lose p53 expression at the level of
translation [221]. Thus, one could argue that the selection of cells defec-
tive in a component that regulates translation of p53 mRNA in RP-
deﬁcient zebraﬁsh could also play a role in their progression to MPNST.
An alternative explanation for tumorigenesis in these zebraﬁsh
models could be that decreased numbers of ribosomes impair selective
translational upregulation of mRNAs encoding for the key tumor sup-
pressor p53. Consistent with this suggestion, selective defects in the
translational upregulation of IRES-containing mRNAs, including p53mRNA, were observed in patients with X-linked dyskeratosis congenita
(DKC), the rare multisystemic syndrome which is caused by mutations
of the DKC1 gene encoding dyskerin, a highly conserved pseudouridine
synthase that catalyzes pseudouridylation of rRNA [206,222]. This de-
fect in translational upregulation of IRES-containing mRNAs was traced
to a decreased pseudouridination of rRNA, which affects the afﬁnity of
the ribosome for these mRNAs [206,223], and it was suggested to be re-
sponsible for an enhanced susceptibility to cancer in these patients
[206,223]. The idea that p53 acts as a major barrier to tumorigenesis
caused by impairment of ribosome biogenesis was also supported by
studies of the 5q-syndrome in humans. Nuclear p53 accumulates in ery-
throid progenitor cells from these patients [58,200] and it is responsible
for the failure of erythropoiesis [192]. By using sensitive deep-
sequencing technology, it was recently demonstrated that TP53 muta-
tions occur in almost a ﬁfth of 5q-MDS patients. Importantly, these mu-
tations were associated with an increased risk of developing acute
myeloid leukemia [224]. Taken together, the selection of cells that lost
expression of wild-type p53 or acquired mutations in p53 or other sig-
naling components of the RP–Mdm2–p53 signaling pathway may
allow the pre-neoplastic cells to escape from the ribosome biogenesis
stress-imposed checkpoint, thereby facilitating malignant transforma-
tion and tumor progression. These cells could also be unresponsive to
some other exogenous or endogenous stresses that upregulate p53, put-
ting them at an even greater risk of malignancy [23,24]. In addition to
abrogating the tumor suppressor functions of wild-type p53, p53muta-
tions may also endow the mutant protein with new activities that can
contribute to various stages of transformation and tumor progression
as well as to increased resistance to anticancer treatments [225].
Although accumulating evidence suggests that RPL5 and RPL11 may
play a role in tumor suppression by upregulating the p53 responses and
inhibiting c-Myc function, no direct in vivo proof has yet been reported
to verify RPL5 and RPL11 as bona ﬁde tumor suppressors [22,133–135].
It might be predicted that mutations in RPL5 and RPL11 could have aris-
en in cancer cells to allow them to escape potential tumor suppressive
functions of these RPs. Identiﬁcation of cancer-associated RPL5 and
RPL11 mutations and characterization of their functional signiﬁcance
in vitro and in vivo will be needed to demonstrate conclusively that
RPL5 and RPL11 are bona ﬁde tumor suppressors. The possibility exists
that in vivo effects of these mutations on tumorigenesis may not be the
equivalent to the Mdm2C305F mutation [30], as RPL5 and RPL11 may
have Mdm2-independent functions [133–135].
9. Conclusion
Intense research efforts over the last decade have revealed the exis-
tence of a p53-activating checkpoint signaling pathway triggered by im-
paired ribosome biogenesis with implications for the pathogenesis of
human diseases [19,22,33,94]. The importance of RPL5, RPL11 and 5S
rRNA in the regulation of the Mdm2–MdmX–p53 module upon impair-
ments of ribosome biogenesis appears well established. On the other
hand, additional studies will be necessary to unambiguously ascribe
“p53-activating” functions to other RPs previously shown to bind
Mdm2 under these conditions. A systematic approach will be required
to identify additional components of this novel checkpoint signaling
pathway, including those involved in sensing the lesion in ribosome
biogenesis, transmitting the signals to the Mdm2–MdmX–p53 module
and integrating it with signaling pathways that regulate other biological
processes. Since many genotoxic and non-genotoxic stressors compro-
mise ribosome biogenesis and nucleolar structure, it will be important
to gain insights into the functional interplay between ribosome biogen-
esis stress checkpoint signaling pathway with other stress signaling
pathways, such as the DDR and oncogenic signaling [37]. Classiﬁcation
of the molecular functions of nucleolar proteins suggests that only 30%
participate in ribosome biogenesis. The other functions include regula-
tion of telomerase function, senescence, aging, biogenesis of multiple
RNPs, apoptosis, viral infection, DNA replication, and repair [149]. It
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contribute to the pathogenesis of ribosomophaties via alteration of
these functions. It also remains to be determinedwhether themolecular
mechanisms that lead to degradation of the aberrant pre-ribosomal as-
semblies are an integral part of the ribosome biogenesis stress check-
point. The most challenging questions in the ﬁeld are related to the
genetic manipulation of ribosome biogenesis stress checkpoint genes
in mice and other model organisms. It will be of paramount importance
to elucidatewhether normal functions of the ribosome biogenesis stress
checkpoint are compromised in various human diseases. The results of
the aforementioned studies will contribute to a better understanding
of the pathogenesis of a number of human diseases, including
ribosomopathies and cancer, as well as guiding the development of
new therapeutic approaches for these diseases.
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